DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ULTRAVIST 300

« Back to Dashboard

All Clinical Trials for Ultravist 300

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00244140 ↗	Ultravist: Safety and Efficacy in Computed Tomography of Head and Body	Completed	Bayer	Phase 3	2005-10-01	This is a research study involving the use of a contrast agent called Ultravist Injection. Ultravist, the study drug, is used to improve the pictures obtained using computed tomography (CT). Ultravist acts like a dye to make CT pictures brighter and easier to read. In the case of this study, it will be injected into a vein in the patient's arm; from there, it travels through the blood stream and to the areas to be examined. CT scans will then be taken of the patient's head and/or body as ordered by his/her physician. Phase IIIb Study to Document the Safety and Efficacy of Ultravist 370 mg I/ml, When Administered Intravenously, in Volumes up to 162.2 ml, for Clinically Indicated Contrast Enhanced Computed Tomography (CECT) of the Head and/or Body
NCT00876083 ↗	PMS Study Ultravist-IMAGE, IoproMide (UltrAvist) to Gain Further Information on Tolerability and Safety in X-ray Examination	Completed	Bayer	N/A	2008-03-01	The purpose of this study is to obtain data on the safety and efficacy of Ultravist application in usual daily use.The radiologist will administer the contrast medium to the patient as he/she would have done without the study. No other examinations will be performed than would have been done routinely.
NCT00926562 ↗	A Safety Comparison of Iopromide and Iodixanol in Renal Impaired Patients	Completed	Chinese PLA General Hospital	Phase 4	2009-02-01	The investigators intend to find out which contrast agent has less kidney toxicity in renal impaired patients undergoing cardiac angiography or percutaneous coronary intervention (PCI).
NCT01206257 ↗	The Safety and toleRability of UltraviSt in Patients Undergoing Cardiac CaTheterization (TRUST)	Completed	Bayer	N/A	2010-08-01	This study is to collect the information of Ultravist® in the patients indicated for the coronary angiography or PCI, like rate of ADR in patients, the dose for different indications, image quality to prove Ultravist the good safety and effectivity

Clinical Trial Conditions for Ultravist 300

Condition Name

Condition Name for Ultravist 300
Intervention	Trials
Diagnostic Imaging	3
Kidney Failure, Chronic	2
Hypothyroidism	1
Coronary Artery Disease	1

Condition MeSH

Condition MeSH for Ultravist 300
Intervention	Trials
Renal Insufficiency	2
Kidney Failure, Chronic	2
Kidney Diseases	1
Myocardial Ischemia	1

Clinical Trial Locations for Ultravist 300

Trials by Country

Trials by Country for Ultravist 300
Location	Trials
China	23
United States	11
Korea, Republic of	3
Colombia	2
Italy	1

Trials by US State

Trials by US State for Ultravist 300
Location	Trials
South Carolina	1
Pennsylvania	1
Ohio	1
New York	1
Michigan	1

Clinical Trial Progress for Ultravist 300

Clinical Trial Phase

Clinical Trial Phase for Ultravist 300
Clinical Trial Phase	Trials
Phase 4	5
Phase 3	1
Phase 2	1

Clinical Trial Status

Clinical Trial Status for Ultravist 300
Clinical Trial Phase	Trials
Completed	8
Unknown status	2
Not yet recruiting	1

Clinical Trial Sponsors for Ultravist 300

Sponsor Name

Sponsor Name for Ultravist 300
Sponsor	Trials
Bayer	5
Seoul National University Hospital	1
Yong Huo	1

Sponsor Type

Sponsor Type for Ultravist 300
Sponsor	Trials
Industry	7
Other	6